Category: 1346157-13-8

On December 27, 2018, Davoren, Jennifer E.; Nason, Deane; Coe, Jotham; Dlugolenski, Keith; Helal, Christopher; Harris, Anthony R.; LaChapelle, Erik; Liang, Sidney; Liu, Yue; OConnor, Rebecca; Orozco, Christine C.; Rai, Brajesh K.; Salafia, Michelle; Samas, Brian; Xu, Wenjian; Kozak, Rouba; Gray, David published an article.Recommanded Product: 5-Bromo-6-methylimidazo[1,2-a]pyridine The title of the article was Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. And the article contained the following:

The discovery of D1 subtype-selective agonists with drug-like properties has been an enduring challenge for the greater part of 40 years. All known D1-selective agonists are catecholamines that bring about receptor desensitization and undergo rapid metabolism, thus limiting their utility as a therapeutic for chronic illness such as schizophrenia and Parkinson’s disease. Our high-throughput screening efforts on D1 yielded a single non-catecholamine hit PF-4211 (6) that was developed into a series of potent D1 receptor agonist leads with high oral bioavailability and CNS penetration. An important structural feature of this series is the locked biaryl ring system resulting in atropisomerism. Disclosed herein is a summary of our hit-to-lead efforts on this series of D1 activators culminating in the discovery of atropisomer 31 (PF-06256142), a potent and selective orthosteric agonist of the D1 receptor that has reduced receptor desensitization relative to dopamine and other catechol-containing agonists. The experimental process involved the reaction of 5-Bromo-6-methylimidazo[1,2-a]pyridine(cas: 1346157-13-8).Recommanded Product: 5-Bromo-6-methylimidazo[1,2-a]pyridine

The Article related to preparation atropisomer dopamine d1 agonist receptor desensitization, schizophrenia parkinson’s dopamine d1 agonist structure, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 5-Bromo-6-methylimidazo[1,2-a]pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Harris, Anthony R.; Nason, Deane M.; Collantes, Elizabeth M.; Xu, Wenjian; Chi, Yushi; Wang, Zhihan; Zhang, Bingzhi; Zhang, Qingjian; Gray, David L.; Davoren, Jennifer E. published an article in 2011, the title of the article was Synthesis of 5-bromo-6-methyl imidazopyrazine, 5-bromo and 5-chloro-6-methyl imidazopyridine using electron density surface maps to guide synthetic strategy.Safety of 5-Bromo-6-methylimidazo[1,2-a]pyridine And the article contains the following content:

Small heteroaromatic rings are valuable monomers in drug discovery that can enable rapid access to novel and desirable chem. space. Installation of a synthetic handle on a heteroaromatic core may be difficult if steric and electronic factors are not in alignment with the desired transformation. Described are practical routes for the construction of 5-bromo-6-Me imidazopyrazine I as well as Me imidazopyridines, e.g., II, developed using electron d. surface maps encoded with ionization potential to guide synthetic strategy. The experimental process involved the reaction of 5-Bromo-6-methylimidazo[1,2-a]pyridine(cas: 1346157-13-8).Safety of 5-Bromo-6-methylimidazo[1,2-a]pyridine

The Article related to bromomethyl imidazopyrazine preparation, methyl imidazopyridine preparation reaction mechanism, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 5-Bromo-6-methylimidazo[1,2-a]pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 15, 2014, Coe, Jotham Wadsworth; Allen, John Arthur; Davoren, Jennifer Elizabeth; Dounay, Amy Beth; Efremov, Ivan Viktorovich; Gray, David Lawrence Firman; Guilmette, Edward Raymond; Harris, Anthony Richard; Helal, Christopher John; Henderson, Jaclyn Louise; Mente, Scot Richard; Nason, Deane Milford, II; O’Neil, Steven Victor; Subramanyam, Chakrapani; Xu, Wenjian published a patent.Formula: C8H7BrN2 The title of the patent was Preparation of heteroaromatic compounds and their use as dopamine D1 ligands for therapy. And the patent contained the following:

The present invention provides, in part, compounds of Formula I (wherein X1 is O or S; Y1 is O, S, or (un)substituted NH; Q1 is Ph, or a N-containing 5-10-membered heterocycloalkyl or heteroaryl, all optionally substituted; RT1 and RT2 are independently H, C1-3-alkyl, cyclopropyl, etc.; R1 is H, F, -C(O)OH, C1-3-fluoroalkyl, etc.; R2 is H, halogen, -CN, -OH, C(O)OH, etc.; R3 and R4 are independently H, C1-6 alkyl, C1-6 haloalkyl, etc.; R5 and R6 are independently H, halogen, -OH, -NO2, -CN, etc.) and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced 尾-arrestin recruitment activity relative to dopamine, D1 agonists interacting significantly with Ser188 but not significantly with Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with both Asp103 and Ser198 of a D1R when binding to the D1R, and their uses in treating neurol., psychiatric and endocrine disorders. Example compound II was prepared in a multistep synthesis that culminated in reaction of intermediate III with 5-bromo-4,6-dimethylpyrimidine. In a human D1 receptor binding assay, II had a Ki of 27.3 nM. The experimental process involved the reaction of 5-Bromo-6-methylimidazo[1,2-a]pyridine(cas: 1346157-13-8).Formula: C8H7BrN2

The Article related to preparation heteroaromatic compound dopamine d1 ligand therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Formula: C8H7BrN2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem